Since the invasion of Ukraine in February 2022, the Russian medical devices market has been affected by technology sanctions and supply chain issues as countries tighten regulations to condemn the Russian government. Since 70% of polymerase chain reaction (PCR) systems are imported, the recent technology sanctions have greatly impacted the market. The global technology sanctions on Russia do not allow the import of PCR systems due to their dual use potential in bioterrorism by the Russian military. Therefore, it is likely that the Russian healthcare system is relying on current PCR system stockpiles and potentially requesting equipment from research labs across the country.
Molecular biology medical device imports have been restricted in Russia as their usage in research may lead to harmful products. For example, in 2011, to study the mammal-to-mammal airborne transmissibility of A/H5N1 avian influenza, scientists enhanced increasing the viruses’ transmissibility in mammals. Although molecular biology equipment is used in healthcare, countries are hesitant to provide Russia with any equipment that has dual-use potential.
The Russian PCR market is projected to slowly increase back to pre-war market values by 2030. However, the conflict is still developing so there may be delays in the market’s recovery.